Tirzepatide (Mounjaro, Zepbound)

FDA-approved context Weight Loss & Metabolism 3 sources

Tirzepatide is a novel, first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Clinical research demonstrates unprecedented efficacy in improving glycemic control in type 2 diabetes and achieving substantial weight loss in individuals with obesity.

01Dosing reference

Amount

Prescription only - dosing determined by physician

Frequency

Prescription only

Cycle

Prescription only

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Dual Receptor Activation

Tirzepatide binds to and activates both GIP and GLP-1 receptors, which are natural incretin hormones.

Metabolic Regulation

This dual activation synergistically enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, and slows gastric emptying.

Appetite Suppression and Weight Loss

The combined signaling in the brain significantly reduces appetite and food intake, leading to profound weight loss and improved metabolic health.

03Human evidence

Substantial weight reduction in obesity

In the SURMOUNT-1 phase 3 clinical trial, participants without diabetes taking the highest dose (15 mg) achieved an average weight loss of 22.5% over 72 weeks.

Superior glycemic control compared to selective GLP-1 agonists

The SURPASS-2 trial demonstrated that tirzepatide provided greater reductions in HbA1c and body weight compared to semaglutide in patients with type 2 diabetes.

04Preclinical evidence

Synergistic effect of GIP and GLP-1

Animal models demonstrated that adding GIP receptor agonism to GLP-1 receptor agonism resulted in greater body weight reduction and food intake suppression than GLP-1 alone.

Improved insulin sensitivity

Preclinical studies in diet-induced obese mice showed that tirzepatide enhanced insulin sensitivity and lipid metabolism more effectively than selective GLP-1 receptor agonists.

05What is known vs. unknown

Reasonably established

Tirzepatide is the first FDA-approved dual GIP/GLP-1 receptor agonist.
It produces weight loss comparable to some bariatric surgeries in clinical trials.
Administered as a once-weekly subcutaneous injection.
Significantly improves cardiometabolic markers, including blood pressure and lipid profiles.

Unknowns & limits

Long-term cardiovascular outcomes are still being evaluated in ongoing trials (e.g., SURPASS-CVOT).
The extent of lean muscle mass loss during rapid weight reduction and strategies to mitigate it require further study.
Weight regain is common upon discontinuation, highlighting the chronic nature of obesity treatment.

06Safety & regulatory context

Regulatory statusTirzepatide is FDA-approved for type 2 diabetes (as Mounjaro) and chronic weight management (as Zepbound). The most common side effects are gastrointestinal, including nausea, diarrhea, vomiting, constipation, and dyspepsia, which are typically dose-dependent and transient. It carries a boxed warning regarding the potential risk of thyroid C-cell tumors, based on findings in rats, and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Other risks include pancreatitis, gallbladder disease, and acute kidney injury.

07Compared with Semaglutide (Wegovy, Ozempic)

Tirzepatide (Mounjaro, Zepbound) vs. Semaglutide (Wegovy, Ozempic)

Key difference

Tirzepatide is a dual GIP and GLP-1 receptor agonist, whereas semaglutide is a selective GLP-1 receptor agonist. Clinical trials generally show greater weight loss and HbA1c reduction with tirzepatide.

When researchers discuss each

Researchers discuss semaglutide when focusing on established cardiovascular benefit data, while tirzepatide is discussed when exploring the enhanced efficacy of multi-receptor incretin therapies.

08Glossary

Incretin

Metabolic hormones released by the gastrointestinal tract after eating that stimulate a decrease in blood glucose levels.

GIP

Glucose-dependent insulinotropic polypeptide, an incretin hormone that stimulates insulin release and regulates fat metabolism.

GLP-1

Glucagon-like peptide-1, an incretin hormone that stimulates insulin secretion, inhibits glucagon release, and reduces appetite.

09Knowledge check

Q1Which two receptors does tirzepatide target?

Q2What is the most common category of side effects associated with tirzepatide?

Q3Which statement best reflects a documented limitation in the evidence about body composition changes with tirzepatide?

Q4When researchers invoke semaglutide in discussions alongside tirzepatide, what context is most commonly being highlighted according to the dossier?

Q5Which explicit contraindication for tirzepatide is described in the dossier's safety and regulatory context?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.